On September 17, 2026, PwC published a market analysis titled "Unlocking the Women's Health Opportunity: A New Era in Fertility and Reproductive Health," projecting the global fertility sector to grow from $25–35 billion today to $35–45 billion by 2030 at a 6–8% compound annual growth rate. The core argument is not the number — it's the structural pivot underneath it: the category is shifting from reactive infertility intervention toward proactive, lifelong reproductive health management, and capital is repricing accordingly.

Why It Matters

Afterglow has been watching this rotation happen in real time without a label for it. In the past ten days alone: Evvy's $40M Series B for vaginal microbiome diagnostics pushing into fertility and IVF, Teal Health's $22M for FDA-authorized at-home cervical screening, Bird&Be's $13M for preconception supplements and at-home tests, Aitiologic's €6.4M for a preeclampsia liquid biopsy, and a $12.8M NIH award to build computational models of female hormone pharmacokinetics. Every one of those is upstream of the clinic — diagnostics, data, and prevention rather than treatment delivery. PwC's report is the framework that explains why they all closed in the same month. For operators, the takeaway is a positioning one. The proactive/preventive framing is not marketing gloss anymore; it's where the 6–8% CAGR lives and where the venture money has moved. For anyone selling into the category, PwC's cleared-versus-unvalidated divide is the practical test: regulatory clearance and reimbursement eligibility are becoming the line between a fundable diagnostics company and a consumer gadget with a shelf life.

The demographic evidence PwC leans on is straightforward. Elective egg freezing cycles in the U.S. grew nearly 4x between 2014 and 2021. The average age of first-time American mothers rose from 24.9 years in 2000 to 27.5 in 2023. Family-building pathways have widened — treatment among same-sex couples more than doubled in the UK between 2012 and 2022 — alongside growth in single parents by choice and donor-assisted conception. None of those are infertility patients in the classical sense. They are healthy people buying optionality, which is a fundamentally different product.

The capital story is the sharpest part of the report. PwC describes an initial wave of private equity clinic roll-ups that deployed over $14 billion between 2020 and 2025, consolidating fragmented independent practices into regional platforms — and says that wave has largely built the operational infrastructure it set out to build. What's replacing it is venture and growth equity: nearly 400 VC funding rounds over the same five-year period, concentrated upstream in precision diagnostics, AI laboratory tools, tech-enabled benefits managers and condition-specific therapeutics. Roll-up is out; picks-and-shovels is in.

Two specifics are worth flagging. On AI in the embryology lab, PwC cites baseline research in which embryologists averaged 51.9% accuracy predicting implantation — barely above a coin flip — versus 62.5% for deep learning time-lapse models. On the payer side, 25% of U.S. employers with 500+ employees offer or plan dedicated fertility benefits in 2026, and as of March 2026, 25 states plus Washington, D.C. have enacted private insurance fertility coverage mandates. PwC also flags PCOS — affecting 10–13% of women globally with no FDA-approved fertility drug — as the clearest unserved pharmaceutical opportunity in the category.

The report's most useful warning for anyone in consumer sexual and reproductive health: PwC sees "a sharp commercial divide" emerging in direct-to-consumer between FDA-cleared, HSA/FSA-eligible diagnostic devices — quantitative progesterone confirmation is the example given — and unvalidated consumer wellness gadgets. That is the fault line the next round of femtech funding will be sorted along.

Sources

Update — 2026-09-23

Initial entry — story first created.